Research programme: ophthalmic disease therapeutics controlled-release - Allergan/InnoCoreAlternative Names: Intra-ocular implant - InnoCore; Intra-ocular microspheres - InnoCore; Sustained release ophthalmic disease therapeutics - Allergan/InnoCore
Latest Information Update: 05 Aug 2015
At a glance
- Originator Allergan
- Developer Allergan; InnoCore Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 22 Oct 2013 Preclinical trials in Eye disorders in Netherlands (Ophthalmic, controlled release)